Cover Image
市場調查報告書

Galleon Pharmaceuticals- 產品平台檢討

Galleon Pharmaceuticals - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293919
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
Galleon Pharmaceuticals- 產品平台檢討 Galleon Pharmaceuticals - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 22 Pages
簡介

Galleon Pharmaceuticals是總公司在美國的製藥企業,正從事睡眠時無呼吸及呼吸障礙的治療藥之藥物研發·開發·上市。平台產品有針對接受手術或重症加護患者及睡眠呼吸中止症患者所用的輔助呼吸用靜脈注射低分子藥的GAL-021,還有睡眠呼吸中止症的口服治療藥候補的GLN- 21,160等。

本報告提供Galleon Pharmaceuticals的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Galleon Pharmaceuticals的基本資料

  • Galleon Pharmaceuticals概要
  • 主要資訊
  • 企業資料

Galleon Pharmaceuticals:R&D概要

  • 主要的治療範圍

Galleon Pharmaceuticals:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Galleon Pharmaceuticals:開發中產品概況

  • 臨床階段的開發中產品
    • PhaseⅠ產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Galleon Pharmaceuticals:藥物簡介

  • GAL-021
  • GAL-160
  • GAL-160 Backups
  • GAL-044

Galleon Pharmaceuticals:開發平台分析

  • 各給藥途徑
  • 各分子類型

Galleon Pharmaceuticals:最新的開發平台資訊

Galleon Pharmaceuticals:開發暫停中的計劃

Galleon Pharmaceuticals:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07068CDB

Summary

Global Markets Direct's, 'Galleon Pharmaceuticals - Product Pipeline Review - 2015', provides an overview of the Galleon Pharmaceuticals's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galleon Pharmaceuticals's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Galleon Pharmaceuticals including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Galleon Pharmaceuticals's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Galleon Pharmaceuticals's pipeline products

Reasons to buy

  • Evaluate Galleon Pharmaceuticals's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Galleon Pharmaceuticals in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Galleon Pharmaceuticals's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Galleon Pharmaceuticals and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galleon Pharmaceuticals
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Galleon Pharmaceuticals and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Galleon Pharmaceuticals Snapshot
    • Galleon Pharmaceuticals Overview
    • Key Information
    • Key Facts
  • Galleon Pharmaceuticals - Research and Development Overview
    • Key Therapeutic Areas
  • Galleon Pharmaceuticals - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Galleon Pharmaceuticals - Pipeline Products Glance
    • Galleon Pharmaceuticals - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Galleon Pharmaceuticals - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Galleon Pharmaceuticals - Drug Profiles
    • GAL-021
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GAL-160
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GAL-160 Backups
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GAL-044
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Galleon Pharmaceuticals - Pipeline Analysis
    • Galleon Pharmaceuticals - Pipeline Products by Route of Administration
    • Galleon Pharmaceuticals - Pipeline Products by Molecule Type
  • Galleon Pharmaceuticals - Recent Pipeline Updates
  • Galleon Pharmaceuticals - Dormant Projects
  • Galleon Pharmaceuticals - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Galleon Pharmaceuticals, Key Information
  • Galleon Pharmaceuticals, Key Facts
  • Galleon Pharmaceuticals - Pipeline by Indication, 2015
  • Galleon Pharmaceuticals - Pipeline by Stage of Development, 2015
  • Galleon Pharmaceuticals - Monotherapy Products in Pipeline, 2015
  • Galleon Pharmaceuticals - Phase I, 2015
  • Galleon Pharmaceuticals - Preclinical, 2015
  • Galleon Pharmaceuticals - Discovery, 2015
  • Galleon Pharmaceuticals - Pipeline by Route of Administration, 2015
  • Galleon Pharmaceuticals - Pipeline by Molecule Type, 2015
  • Galleon Pharmaceuticals - Recent Pipeline Updates, 2015
  • Galleon Pharmaceuticals - Dormant Developmental Projects,2015

List of Figures

  • Galleon Pharmaceuticals - Pipeline by Top 10 Indication, 2015
  • Galleon Pharmaceuticals - Pipeline by Stage of Development, 2015
  • Galleon Pharmaceuticals - Monotherapy Products in Pipeline, 2015
  • Galleon Pharmaceuticals - Pipeline by Top 10 Route of Administration, 2015
  • Galleon Pharmaceuticals - Pipeline by Top 10 Molecule Type, 2015
Back to Top